An alternative of Carcino-Embryonic Antigen (CEA) and Carcinoma Antigen-15-3 (CA-15-3) was proposed by Heneghan et al. (2010), who identified patients with breast cancer with a sensitivity and specificity of 87.7% and 91%, respectively, by measuring the circulating levels of miR-195 [10]. Here, CEACAM5 is linked to breast carcinoma.